Alcon takes another step towards WaveLight acquisition

Article

The German Federal Financial Supervisory Authority has approved publication of Alcon's tender offer document for WaveLight AG. This tender offer marks the second step in the completion of Alcon's acquisition of WaveLight.

The German Federal Financial Supervisory Authority has approved publication of Alcon's tender offer document for WaveLight AG. This tender offer marks the second step in the completion of Alcon's acquisition of WaveLight.

Alcon hopes to increase its stake in WaveLight from 16% of issued shares to at least 75% and, in response to recent trading activity, Alcon has increased its previously announced offer for WaveLight from €10 to €15 per share. The tender offer acceptance period closes on 11th September, 2007.

Alcon isn't the only firm to express an interest in WaveLight, however. Carl Zeiss Meditec has also acquired a 5% shareholding in the firm. The company says that the acquisition of stock demonstrates its interest in a possible voluntary takeover offer. Zeiss believes any takeover would be based on the future earning potential of Wavelight and the possible benefits that could arise from combining the two businesses.

On 20th August, WaveLight's Executive Committee and Supervisory Board recommended that shareholders tender their shares to Alcon.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
© 2025 MJH Life Sciences

All rights reserved.